Novartis's Sandoz Launches EpiPen Generic
January 16 2019 - 5:28PM
Dow Jones News
By Maria Armental
Swiss drug giant Novartis AG is launching a generic version to
Mylan NV's EpiPen, the emergency treatment for allergic reactions
that's been beleaguered by pricing and supply challenges.
Novartis's Sandoz generic-drug unit had bought the U.S.
commercial rights for the emergency shot, Symjepi, from Adamis
Pharmaceuticals Corp. Symjepi, a small device that fits into the
palm of a hand, contains the same active ingredient as EpiPen,
epinephrine, though it's not an exact copy of EpiPen.
It will be available to institutional customers before it's sold
to the public, Sandoz said, and will be first marketed as a 0.3 mg
injection for patients who weigh at least 66 pounds and are
determined to be at a higher risk for anaphylaxis.
The companies are working to launch a 0.15 mg injection to treat
patients who weigh 33 to 65 pounds.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
January 16, 2019 17:13 ET (22:13 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024
